Clostridium (e.g., Clostridium Tetani, Etc.) Patents (Class 424/239.1)
-
Patent number: 8071110Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 15, 2008Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Sanjiv Ghanshani, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
-
Publication number: 20110293663Abstract: Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions.Type: ApplicationFiled: March 3, 2008Publication date: December 1, 2011Inventor: Gary Borodic
-
Patent number: 8067231Abstract: Compositions useful for detecting Clostridial toxin activity comprising a cell that contains an exogenous Clostridial toxin substrate which comprises a fluorescent member, a membrane targeting domain and a Clostridial toxin recognition sequence comprising a cleavage site, where the cleavage site intervenes between the fluorescent member and the membrane targeting domain; and methods useful for determining Clostridial toxin activity using such Clostridial toxin substrates.Type: GrantFiled: April 4, 2006Date of Patent: November 29, 2011Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Lance E. Steward, Kei Roger Aoki
-
Patent number: 8062643Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: GrantFiled: October 27, 2007Date of Patent: November 22, 2011Assignee: The Regents of the University of ColoradoInventor: Richard A Schmidt
-
Publication number: 20110280909Abstract: Methods and systems are described for a rapid and sustainable change in the pigment melanin content of melanocytes of the iris stroma, thereby to change the color of the eye. Also described are nanoparticle compositions for lightening the pigmented tissues or treating a pigmented tissue related disease.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Inventor: Kambiz Thomas Moazed
-
Publication number: 20110280908Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.Type: ApplicationFiled: April 15, 2011Publication date: November 17, 2011Applicants: Services, National Institutes of Health, Office of Technology TransferInventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
-
Patent number: 8057806Abstract: A method to prepare viruses lacking ion channel activity is provided.Type: GrantFiled: January 26, 2005Date of Patent: November 15, 2011Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Patent number: 8057807Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: GrantFiled: October 1, 2008Date of Patent: November 15, 2011Assignee: The Regents of the University of Colorado, a body corporateInventor: Richard A. Schmidt
-
Patent number: 8052979Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.Type: GrantFiled: March 14, 2006Date of Patent: November 8, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
-
Publication number: 20110268805Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface and an immunostimulatory moiety. In some embodiments, the immunostimulatory moiety is an adjuvant. The invention provides pharmaceutical compositions comprising inventive nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive nanocarriers and pharmaceutical compositions thereof.Type: ApplicationFiled: October 9, 2009Publication date: November 3, 2011Inventors: Frank Alexis, Matteo Iannacone, Jinjin Shi, Pamela Basto, Elliott Ashley Moseman, Ulrich von Andrian, Robert S. Langer, Omid C. Farokhzad, Elena Tonti
-
Patent number: 8048423Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: GrantFiled: December 9, 2003Date of Patent: November 1, 2011Assignee: Allergan, Inc.Inventor: Eric R. First
-
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
Patent number: 8044188Abstract: The present invention relates to an isolated Clostridial neurotoxin propeptide having a light chain region, a heavy chain region, where the light and heavy chain regions are linked by a disulfide bond, and an intermediate region connecting the light and heavy chain regions. An isolated nucleic acid molecule encoding a Clostridial neurotoxin propeptide is also disclosed. Also disclosed is an isolated, physiologically active Clostridial neurotoxin produced by cleaving a Clostridial neurotoxin propeptide, a vaccine or antidote thereof, and methods of immunizing against or treating for toxic effects of Clostridial neurotoxins. Methods of expressing recombinant physiologically active Clostridial neurotoxins are also disclosed. Also disclosed is a chimeric protein having a heavy chain region of a Clostridial neurotoxin and a protein with therapeutic functionality. A treatment method is also disclosed.Type: GrantFiled: April 19, 2010Date of Patent: October 25, 2011Assignee: New York UniversityInventors: Konstantin Ichtchenko, Philip A. Band -
Patent number: 8034357Abstract: Methods of using clostridial toxins and other biological agents to thin skin and control fine wrinkles in humans are provided. In preferred embodiments the methods provide beneficial effects in humans.Type: GrantFiled: August 27, 2010Date of Patent: October 11, 2011Inventors: Ira Sanders, Rosemary Aquila-Sanders
-
Publication number: 20110243991Abstract: The invention relates to a process for the production of a vaccine against bacterial pathogens which produce an AB toxin, like Clostridium, comprising (a) culturing the pathogen under conditions where the AB toxin is produced, and harvesting the culture (b) cleaving the AB toxin enzymatically in vitro, preferably using inositol hexaphosphate as a co-factor, and (c) combining the composition of step (b) with a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 1, 2009Publication date: October 6, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventor: Jessica Reineke
-
Patent number: 8025889Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: GrantFiled: December 19, 2008Date of Patent: September 27, 2011Assignee: Allergan, Inc.Inventor: Patricia S. Walker
-
Patent number: 8021645Abstract: A composition for treating a subject is provided. The composition includes antigen specific dimeric secretory IgA and pentameric IgM therapeutic. A process for manufacturing a medicament for the treatment of C. difficile associated disease in a human is also provided that the modification of antigen specific dimeric secretory IgA and pentameric IgM with secretory component to form a antigen specific dimeric secretory IgA and pentameric secretory IgM therapeutic. The antigen specific dimeric secretory IgA and the pentameric secretory IgM therapeutic is then mixed with formulating agents to create a capsule, tablet, liquid or suppository dosing form. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating. A method of C. difficile treatment with the therapeutic is also provided that is amenable to supplementation with concurrent or prior antibiotic administration.Type: GrantFiled: June 13, 2008Date of Patent: September 20, 2011Inventors: Michael R. Simon, Stephanie M. Chervin, Stephen C. Brown
-
Patent number: 8021859Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.Type: GrantFiled: August 15, 2008Date of Patent: September 20, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella A. Gilmore, Kei Roger Aoki
-
Patent number: 8017131Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.Type: GrantFiled: July 18, 2008Date of Patent: September 13, 2011Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 8017134Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: January 27, 2009Date of Patent: September 13, 2011Assignees: Syntaxin Limited, The Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, John Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8012716Abstract: Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceutical compositions. The APF media can contain significantly reduced levels of meat or dairy by-products and use non-animal based products instead of the animal-derived products. Preferably, the APF media used are substantially free or free of animal derived products.Type: GrantFiled: July 10, 2009Date of Patent: September 6, 2011Assignee: Allergan, Inc.Inventors: Stephen Donovan, Ping Wang
-
Patent number: 8012491Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: GrantFiled: February 11, 2009Date of Patent: September 6, 2011Assignees: Syntaxin, Ltd., Health Protection AgencyInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 8007818Abstract: The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide of H. influenzae B (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.Type: GrantFiled: June 14, 2004Date of Patent: August 30, 2011Assignee: GlaxoSmithKline Biologicals, S.R.Inventors: Nathalie Marie-Josephe Garcon, Dominique Lemoine, Florence Emilie Jeanne Francoise Wauters
-
Patent number: 8008044Abstract: Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-products using non-animal based products to replace the animal-derived products. Preferably, the media used are substantially free of animal derived products.Type: GrantFiled: September 19, 2008Date of Patent: August 30, 2011Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Publication number: 20110206731Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: ApplicationFiled: March 28, 2011Publication date: August 25, 2011Applicant: ALLERGAN, INC.Inventor: Eric FIRST
-
Patent number: 8003351Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 22, 2008Date of Patent: August 23, 2011Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Publication number: 20110200639Abstract: Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating the depression.Type: ApplicationFiled: March 22, 2011Publication date: August 18, 2011Applicant: ALLERGAN, INC.Inventor: Andrew M. Blumenfeld
-
Patent number: 7998489Abstract: The specification discloses modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; polynucleotide molecules encoding modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain; and method of producing modified Clostridial toxins comprising a PAR ligand domain, a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and a Clostridial toxin binding domain.Type: GrantFiled: August 15, 2008Date of Patent: August 16, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Ester G. Fernandez-Salas, Marcella A. Gilmore, Joseph Francis, Shengwen Li, Kei Roger Aoki
-
Patent number: 7993656Abstract: The invention provides modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain, a translocation facilitating domain and an altered target domain; polynucleotide molecules encoding such modified Clostridial toxins; and methods of producing such modified Clostridial toxins.Type: GrantFiled: July 11, 2007Date of Patent: August 9, 2011Assignee: Allergan, Inc.Inventors: Lance E. Steward, Joseph Francis, Ester G. Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, Kei Roger Aoki
-
Publication number: 20110184330Abstract: Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.Type: ApplicationFiled: February 1, 2011Publication date: July 28, 2011Applicant: Asthmatx, Inc.Inventors: Michael D. LAUFER, David C. AUTH, Christopher J. DANEK, William J. WIZEMAN, Gary S. KAPLAN
-
Patent number: 7985411Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: August 18, 2008Date of Patent: July 26, 2011Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Publication number: 20110177120Abstract: The present invention relates to the use of live mycobacterium of the M. tuberculosis complex for preparing a medicament, wherein the function of the zmp1-gene is inactivated, pharmaceutical compositions prepared from such mycobacteria as well as a method for the treatment and/or prophylaxis of a disease or medical condition using said pharmaceutical composition.Type: ApplicationFiled: October 9, 2009Publication date: July 21, 2011Applicant: UNIVERSITY OF ZURICHInventors: Erik Boettger, Peter Sander
-
Publication number: 20110177116Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: ApplicationFiled: November 6, 2009Publication date: July 21, 2011Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Patent number: 7982006Abstract: This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cp) ?-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.Type: GrantFiled: June 23, 2010Date of Patent: July 19, 2011Assignee: Dow AgroSciences LLCInventors: William M. Ainley, Janna Armstrong, Krishna Madduri, Donald J. Merlo, Kelley A. Smith, Mark A. Thompson, Steven R. Webb, Liu Y. Shen
-
Patent number: 7981433Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.Type: GrantFiled: May 21, 2010Date of Patent: July 19, 2011Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 7981432Abstract: The invention features a polypeptide complex synthesized by bacteria of the genus Clostridia that contains the serotype E botulinum neurotoxin and five neurotoxin associated polypeptides having molecular weights of about 118, 80, 65, 40, and 18 kDa, respectively. The complex is useful in the treatment of diseases or conditions that are caused by excessive release of acetylcholine from presynaptic nerve terminals.Type: GrantFiled: October 7, 2008Date of Patent: July 19, 2011Assignee: University of MassachusettsInventors: Bal Ram Singh, Zhong Zhang
-
Publication number: 20110165196Abstract: The present invention generally relates to methods for treating cribbing behavior in animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the sternocephalic muscle, thereby denervating these muscles and preventing cribbing behavior.Type: ApplicationFiled: January 4, 2010Publication date: July 7, 2011Inventors: J. Ben Renfroe, Daniel M. Carter
-
Publication number: 20110165195Abstract: A mucosal absorption-enhancing agent is provided that enables oral, nasal or pulmonary administration of peptide drugs whose administration route has heretofore been limited to the injections due to their poor absorption from the mucosa. Specifically, the mucosal absorption of peptide drugs via intestinal, pulmonary or nasal route can be enhanced by allowing the peptide drugs with the C-terminal fragment (C-CPE) of an enterotoxin (CPE) produced by the bacterium Clostridium perfringens of the genus Clostridium, in particular with the C-CPE or its mutants resulting from the substitution and/or deletion of one or several amino acid residues of the C-CPE to act thereon. The composition for mucosal administration of the present invention significantly enhances absorption of peptide drugs, such as human parathyroid hormone hPTH(1-34), human ghrelin and human motilin, through the mucosa of small intestine, lung, nasal cavity and other mucosa.Type: ApplicationFiled: June 27, 2008Publication date: July 7, 2011Applicant: Asubio Pharma Co., LtdInventors: Masuo Kondoh, Hiroshi Uchida, Takeshi Hanada, Masato Hoshino
-
Patent number: 7972604Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.Type: GrantFiled: August 27, 2010Date of Patent: July 5, 2011Assignee: Intervet Inc.Inventors: Mark D. Cochran, Gary R. Peterson, Stephen V. Lair, Richard M. Synenki
-
Patent number: 7972608Abstract: The present invention provides, among other things, improved carrier proteins for antigen-based vaccines, including polysaccharide-based vaccines. An aspect of the invention advantageously employs tetanus toxin Fragment C.Type: GrantFiled: June 23, 2004Date of Patent: July 5, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: John Kim, Francis J. Michon
-
Patent number: 7968104Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.Type: GrantFiled: June 4, 2008Date of Patent: June 28, 2011Assignee: Allergan, Inc.Inventor: Richard A Schmidt
-
Publication number: 20110150975Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: ApplicationFiled: December 22, 2010Publication date: June 23, 2011Inventor: Ira Sanders
-
Publication number: 20110142882Abstract: Methods for controlling abnormal blood flow in disease states by the selective alteration of the components of microvascular flow using Botulinum A Toxin, other SNARE protein mediating agents, alpha adrenergic agents, and other compounds is heretofore unknown, whether delivered by injection, topical application, or transdermal means. The invention discloses novel methods for the control of blood flow in skin, subcutaneous tissue and muscle by botulinum toxin, snare protein mediating substances, and alpha adrenergic agents by either injection or transdermal delivery systems.Type: ApplicationFiled: December 16, 2009Publication date: June 16, 2011Inventors: L. Andrew Koman, Thomas Smith
-
Patent number: 7959933Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.Type: GrantFiled: July 30, 2008Date of Patent: June 14, 2011Assignee: Allergan, Inc.Inventors: J. Oliver Dolly, Yan Li, Kuo Chion Chan
-
Patent number: 7943152Abstract: Chalazia and hordeola are the most common lesions occurring in the human eyelid, and often recurrences are managed by surgical intervention to remove fatty inclusions within the lid with associated inflammatory reaction. The present invention provides non-surgical methods of treating chalazia, hordeola and cutaneous infections comprising the administration of compositions comprising botulinum toxin. The present invention provides methods that effectively block meibum secretion from the meibomian glands, reduce sebaceous bacterial culture media on skin, and sebaceous secretion from the glands of Zeis. Decreased production of meibum and associated fatty substances resulting from the methods of the present invention, decrease gland blockage and tissue inspissations, resulting in reduced recurrence of chalazia, hordeola and related inflammatory reactions and lesions.Type: GrantFiled: January 22, 2008Date of Patent: May 17, 2011Assignee: Botulinum Toxin Research Associates, Inc.Inventor: Gary Borodic
-
Publication number: 20110104206Abstract: The present disclosure relates to methods and compositions for the topical sustained delivery of therapeutic agents. Topical application of compositions containing a muscle fasciculating agent result in the sustained release of any therapeutic agent contained within the composition. More particularly, topical application of such compositions to the outer surface of the eyelid of a patient results in increased absorption and sustained release of the therapeutic agent into the eyes or systemically.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Inventors: Padma NANDURI, T. Aaron DYER
-
Publication number: 20110091505Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: ApplicationFiled: December 22, 2010Publication date: April 21, 2011Inventor: Ira Sanders
-
Publication number: 20110091504Abstract: A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.Type: ApplicationFiled: December 22, 2010Publication date: April 21, 2011Inventor: Ira Sanders
-
Publication number: 20110091503Abstract: The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from Clostridium botulinum, the neurotoxin being free of the complexing proteins naturally present in the botulinum neurotoxin complex or being chemically modified or being modified by genetic manipulation. Moreover the pharmaceutical compositions of the instant invention have good stability and are advantageously formulated free of human serum albumin.Type: ApplicationFiled: December 22, 2010Publication date: April 21, 2011Applicant: MERZ PHARMA GmbH & CO. KGaAInventor: Harold Victor Taylor
-
Publication number: 20110076305Abstract: Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvant may also be described as a heterologous acellular collagenous tissue preparation. The adjuvants are demonstrated to enhance the immunogencity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal.Type: ApplicationFiled: August 26, 2010Publication date: March 31, 2011Applicants: University of Notre Dame Du Lac, Cook Biotech, Inc.Inventors: Mark A. Suckow, William R. Wolter, Paul J. Hall
-
Patent number: 7906124Abstract: Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit.Type: GrantFiled: September 30, 2004Date of Patent: March 15, 2011Assignee: Asthmatx, Inc.Inventors: Michael D. Laufer, David C. Auth, Christopher J. Danek, William J. Wizeman, Gary S. Kaplan